Schimmelpennink Evert B. 4
4 · LENZ Therapeutics, Inc. · Filed Jul 23, 2024
Insider Transaction Report
Form 4
Schimmelpennink Evert B.
DirectorPresident, CEO and Secretary
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2024-07-22−45,000→ 342,106 totalExercise: $1.04Exp: 2031-03-07→ Common Stock (45,000 underlying) - Exercise/Conversion
Common Stock
2024-07-22$1.04/sh+45,000$46,800→ 45,000 total
Footnotes (1)
- [F1]Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 8, 2021.